A protein on the surface of cells may help abnormal cells keep growing after they break away from surrounding tissue, a key step toward cancer spread.
Researchers in Brazil found that switching off this protein, called syndecan-4 or SDC4, stopped rapid cell division and restored a natural self-destruct response in laboratory cells.
Published on March 24, 2026, the finding points to a possible target for future cancer treatments and perhaps a marker for tracking tumor progression.
This is early work in rabbit blood-vessel cells, however, not a treatment tested in human tumors, animals, or patients, so the distance from a laboratory brake to a medical therapy remains substantial.
Why detached cells usually die
Healthy tissue is not just a pile of cells. Most cells stay anchored to neighboring cells and to the extracellular matrix, a web of proteins and sugars that fills the spaces between them and helps hold the tissue together.
When a normal cell loses that anchor, it can activate anoikis, a form of programmed death. The Greek-derived name roughly means death without a home, which captures the basic idea. A cell in the wrong place is told to shut down.
How cancer cells escape
Aggressive cancer cells can bend that safety rule. They may survive after detaching, move through the bloodstream, and settle in another organ, a process called metastasis.
Why does that matter so much? A cell that cannot survive the trip cannot build a new tumor far from the original one. Resistance to anoikis therefore acts like a travel permit for cancer spread, and SDC4 appears to help issue it.
SDC4 acts like a shield
SDC4 normally helps cells attach to tissue and respond to growth signals. Trouble may begin when cells make too much of it, because high SDC4 levels have been linked with stronger survival, movement, invasion, and other cancer-like behavior.
Carla Cristina Lopes, a biological sciences professor at the Federal University of São Paulo (FAPESP) and the paper’s corresponding author, said, “Our study shows that SDC4 could become a promising therapeutic target and serve as a diagnostic marker for monitoring disease progression.”
The study formed part of first author Bianca Zaia Franco Ferreira’s master’s research supported by FAPESP.
How the experiment worked
The researchers studied endothelial cells taken from a rabbit aorta. They compared ordinary cells, cells altered with a cancer-related Ras gene, cells trained to resist anoikis, and resistant cells in which SDC4 had been genetically silenced.
The team kept cells from attaching to a surface for four days. Fewer than 5% of the original cells survived that loss of contact, but the survivors became highly aggressive and produced unusually large amounts of SDC4. In the selected silenced line, SDC4 production fell by about 90%.
The biological brake returned
Once SDC4 was switched off, the resistant cells became more dependent on physical attachment and more vulnerable to programmed death. Their invasive behavior also fell, suggesting that the same change affected both survival in suspension and the ability to push into nearby tissue.
The team also saw more p27, a protein that works like a stop signal early in cell division. It blocked progress at the restriction point, the checkpoint where a cell commits to copying its DNA.
A combined score for cyclin proteins fell by more than half, while a related enzyme score dropped by roughly one-quarter.
Earlier clues now fit together
This result builds on 2014 research showing that cells which acquired anoikis resistance also increased SDC4 production. A 2020 follow-up study found that silencing the protein reduced proliferation, invasion, and blood-vessel-forming behavior while making the abnormal cells more likely to die.
More recent research on cell adhesion found that lowering SDC4 changed how resistant cells attached to the extracellular matrix and altered proteins involved in movement.
Taken together, the studies suggest SDC4 is not a single on-off button but part of a wider control panel linking attachment, growth, and survival.
What the findings do not prove
The biggest limitation is the model itself. These were rabbit endothelial cells grown in dishes, and although they displayed cancer-like traits, they were not human tumor samples. The team must now repeat the work in human cells, including cancer cells, before the idea can move closer to clinical research.
SDC4 also performs useful jobs in healthy tissue, so a future treatment would need to block harmful activity without disrupting normal healing, adhesion, or blood-vessel function. The study cannot yet show which cancers might respond, what dose would be safe, or whether tumors could find another escape route.
CBD is one possible next test
The group is now examining whether cannabidiol, the nonintoxicating cannabis compound known as CBD, can change SDC4 levels or interrupt the signaling pathways that support uncontrolled growth. That idea is still at an early laboratory stage and does not show that CBD treats cancer.
The research received additional funding from the Brazilian agencies CNPq, CAPES, and FINEP. The next decisive step is replication in human tumor cells, followed by studies that separate a promising molecular target from a treatment that actually helps patients.
The main study has been published in Cytotechnology.
